
In terms of the primary endpoint, the rPFS was 90% in Arm A and 78% in Arm B. This is a small study but these values compare favorably to the patients in COUGAR 302, where the rPFS at 1 year was around 60%. The time to PSA progression was 9.6 months in Arm A and 11.2 months in Arm B – these are similar to COUGAR 302, where the median time to PSA progression was 11.1 months. Neither the time to PSA progression or rate of rPFS at 1 year was significantly different between the two arms. Of note, 6 patients in Arm B had testosterone levels arise above castrate levels within 28 days of discontinuation of abiraterone/prednisone.

Presented by: Carsten Henning Ohlmann, MD, Malteser Hospital Bonn, Bonn, Germany
Written by: Jason Zhu, MD. Fellow, Division of Hematology and Oncology, Duke University, @TheRealJasonZhu at the 2019 ASCO Annual Meeting #ASCO19, May 31-June 4, 2019, Chicago, IL USA
References:
- De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine 2011;364:1995-2005.
- Ryan CJ, Smith MR, De Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. New England Journal of Medicine 2013;368:138-48.